Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Gattei

Showing results (151-160 of 190) with videos related to

Pageof 19
Sort By:
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Blood|January 27, 2011
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformationDavide Rossi, Valeria Spina, Clara Deambrogi, et al.
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological featuresRiccardo Bomben, Michele Dal-Bo, Dania Benedetti, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Leukemia|June 24, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemiaFederico Pozzo, Gabriela Forestieri, Filippo Vit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndromeDavide Rossi, Valeria Spina, Michaela Cerri, et al.
Genes, Chromosomes & Cancer|May 13, 2011
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemiaMichele Dal Bo, Francesca Maria Rossi, Davide Rossi, et al.
Pageof 19

Showing results (151-160 of 190) with videos related to

Sort By:
Pageof 19
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Blood|January 27, 2011
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformationDavide Rossi, Valeria Spina, Clara Deambrogi, et al.
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological featuresRiccardo Bomben, Michele Dal-Bo, Dania Benedetti, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Leukemia|June 24, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemiaFederico Pozzo, Gabriela Forestieri, Filippo Vit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndromeDavide Rossi, Valeria Spina, Michaela Cerri, et al.
Genes, Chromosomes & Cancer|May 13, 2011
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemiaMichele Dal Bo, Francesca Maria Rossi, Davide Rossi, et al.
Pageof 19